0R1F Stock Overview
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide.
Snowflake Score | |
---|---|
Valuation | 5/6 |
Future Growth | 2/6 |
Past Performance | 5/6 |
Financial Health | 3/6 |
Dividends | 5/6 |
Bristol-Myers Squibb Company Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | US$48.07 |
52 Week High | US$70.81 |
52 Week Low | US$47.58 |
Beta | 0.39 |
1 Month Change | -7.34% |
3 Month Change | -4.07% |
1 Year Change | -31.67% |
3 Year Change | -27.59% |
5 Year Change | 6.69% |
Change since IPO | -14.11% |
Recent News & Updates
Recent updates
Shareholder Returns
0R1F | GB Pharmaceuticals | GB Market | |
---|---|---|---|
7D | -1.4% | -1.2% | -0.7% |
1Y | -31.7% | -5.0% | -1.8% |
Return vs Industry: 0R1F underperformed the UK Pharmaceuticals industry which returned -5% over the past year.
Return vs Market: 0R1F underperformed the UK Market which returned -1.8% over the past year.
Price Volatility
0R1F volatility | |
---|---|
0R1F Average Weekly Movement | 2.8% |
Pharmaceuticals Industry Average Movement | 8.7% |
Market Average Movement | 4.8% |
10% most volatile stocks in GB Market | 11.5% |
10% least volatile stocks in GB Market | 2.6% |
Stable Share Price: 0R1F has not had significant price volatility in the past 3 months.
Volatility Over Time: 0R1F's weekly volatility (3%) has been stable over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
1887 | 34,100 | Chris Boerner | www.bms.com |
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company’s products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.
Bristol-Myers Squibb Company Fundamentals Summary
0R1F fundamental statistics | |
---|---|
Market cap | US$97.89b |
Earnings (TTM) | US$8.03b |
Revenue (TTM) | US$45.01b |
12.2x
P/E Ratio2.2x
P/S RatioIs 0R1F overvalued?
See Fair Value and valuation analysisEarnings & Revenue
0R1F income statement (TTM) | |
---|---|
Revenue | US$45.01b |
Cost of Revenue | US$10.52b |
Gross Profit | US$34.49b |
Other Expenses | US$26.46b |
Earnings | US$8.03b |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
Apr 25, 2024
Earnings per share (EPS) | 3.96 |
Gross Margin | 76.63% |
Net Profit Margin | 17.83% |
Debt/Equity Ratio | 135.1% |
How did 0R1F perform over the long term?
See historical performance and comparison